Thursday, November 21, 2024 11/21/2024

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients with Community-Acquired Pneumonia

Award Number: R01HS028633
ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY
OPDIV: AHRQ
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary/Abstract Community-acquired pneumonia (CAP) is a leading cause of hospitalizations and inpatient morbidity and mortality in the United States. However, the etiological diagnosis of CAP is challenging as >75% of cultures are negative and a causative pathogen cannot be identified. The ATS/IDSA guidelines recommend that extended spectrum empiric antimicrobial therapy be limited to adult patients with risk factors for resistant pathogens. However, in the face of negative cultures and diagnostic uncertainty, clinicians are often uncomfortable de- escalating therapy, because narrowing treatment could result in inadequate coverage. The prolongation of empiric treatment hampers antimicrobial stewardship efforts and encourages the development of antimicrobial resistance. Our overall goal is to improve antimicrobial prescribing for patients with CAP by emphasizing pathogen-directed therapy. An accurate pathogenic diagnosis could contribute to antimicrobial stewardship in 2 ways: 1) by allowing for initial narrow-spectrum therapy and 2) by providing confidence when de-escalating therapy following negative cultures. Rapid diagnostic assays have the potential to provide accurate results within hours and thereby reduce the duration of exposure to extended spectrum empiric therapy. Multiple observational studies have demonstrated that use of molecular diagnostic assays is associated with favorable outcomes including a reduction in the total duration of antimicrobial use and length of stay in the hospital. The most recent antimicrobial stewardship implementation guidelines recommend the use of rapid viral testing for respiratory pathogens as a means to reduce the use of inappropriate antibiotics. However, these recommendations are based on low quality evidence and it is unknown whether more widespread early diagnostic testing could reduce the use of broad-spectrum antibiotics and/or prompt initiation of antiviral therapy. De-escalation following negative bacterial cultures is another antimicrobial stewardship target. While most de-escalation follows identification of a susceptible pathogen, the ATS/IDSA guidelines also recommend de-escalation at 48 hours if cultures are negative. However, these recommendations are also based on observational studies. We propose a large, multicenter 2 X 2 factorial cluster randomized controlled trial to test both approaches to reducing the use of broad-spectrum antibiotics in patients with CAP: a) routine use of rapid diagnostic testing at the time of admission and b) pharmacist-led de-escalation after 48 hours for clinically stable patients with negative cultures. Our study will be the largest randomized trial to determine the impact of rapid diagnostic testing on antimicrobial stewardship and patient outcomes. Our randomized trial design will allow us to establish causality and determine whether broad spectrum antibiotics can be safely de-escalated in stable patients. Findings from our proposed trials will generate important new knowledge about pathogen targeted therapy and antimicrobial de-escalation in patients with CAP. Specifically, knowledge gained from this proposal will allow physicians to limit the use of broad-spectrum antimicrobials and initiate targeted therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $500,000 )
2024	2024	THE CLEVELAND CLINIC FOUNDATION	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Research on Healthcare Costs, Quality and Outcomes	000	4	8/5/2024	NON-COMPETING CONTINUATION	$500,000
														Subtotal = $500,000

Issue Date FY: 2023 ( Subtotal = $500,000 )
2023	2023	THE CLEVELAND CLINIC FOUNDATION	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Research on Healthcare Costs, Quality and Outcomes	000	3	8/11/2023	NON-COMPETING CONTINUATION	$500,000
														Subtotal = $500,000

Issue Date FY: 2022 ( Subtotal = $500,000 )
2022	2022	CLEVELAND CLINIC FOUNDATION	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Research on Healthcare Costs, Quality and Outcomes	000	2	8/17/2022	NON-COMPETING CONTINUATION	$500,000
														Subtotal = $500,000

Issue Date FY: 2021 ( Subtotal = $499,999 )
2021	2021	CLEVELAND CLINIC FOUNDATION, THE	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Research on Healthcare Costs, Quality and Outcomes	000	1	9/13/2021	NEW	$499,999
														Subtotal = $499,999

Grand Total All Awards = $1,999,999

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients with Community-Acquired Pneumonia

Award Number: R01HS028633

ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY

OPDIV: AHRQ

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer